Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis

English version České info

Background:
Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.

Methods and Findings:
We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.

Conclusions:
In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis. PLoS Med 9(11): e32767. doi:10.1371/journal.pmed.1001348
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001348

Souhrn

Zdroje

1. World Health Organization (2010) Global tuberculosis control 2010. Geneva: World Health Organization.

2. ConinxR, MaherD, ReyesH, GrzemskaM (2000) Tuberculosis in prisons in countries with high prevalence. BMJ 320: 440–442.

3. StucklerD, BasuS, McKeeM, KingL (2008) Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci U S A 105: 13280–13285 doi:10.1073/pnas.0801200105.

4. Dara M, Grzemska M, Kimerling ME, Reyes H, Zagorskiy A (2009) Guidelines for control of tuberculosis in prisons. Washington (District of Columbia): U.S. Agency for International Development.

5. Bone A, Aerts A, Grzemska M, Kimerling M, Kluge H, et al.. (2000) Tuberculosis control in prisons: a manual for programme managers. Geneva: World Health Organization.

6. BelovIB, KitaevVM (2000) [Comparative assessment of diagnostic capacities of thoracic fluorography, film x-ray study and small-dose digital x-ray study.]. Probl Tuberk 6: 23–27.

7. LegrandJ, SanchezA, Le PontF, CamachoL, LarouzeB (2008) Modeling the impact of tuberculosis control strategies in highly endemic overcrowded prisons. PLoS ONE 3: e2100 doi:10.1371/journal.pone.0002100.

8. van der WerfMJ, EnarsonDA, BorgdorffMW (2008) How to identify tuberculosis cases in a prevalence survey. Int J Tuberc Lung Dis 12: 1255–1260.

9. ShinSS, PasechnikovAD, GelmanovaIY, PeremitinGG, StrelisAK, et al. (2006) Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 10: 402–408.

10. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.

11. SohnH, MinionJ, AlbertH, DhedaK, PaiM (2009) TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther 7: 723–733 doi:10.1586/eri.09.52.

12. International Labour Organization (2011) LABORSTA Internet: statistics by country [database]. Geneva: International Labour Organization.

13. World Health Organization (2011) Unit costs for patient services. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Geneva: World Health Organzation.

14. VassallA, van KampenS, SohnH, MichaelJS, JohnKR, et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 8: e1001120 doi:10.1371/journal.pmed.1001120.

15. SackettDL, TorranceGW (1978) The utility of different health states as perceived by the general public. J Chronic Dis 31: 697–704.

16. GuoN, MarraCA, MarraF, MoadebiS, ElwoodRK, et al. (2008) Health state utilities in latent and active tuberculosis. Value Health 11: 1154–1161 doi:10.1111/j.1524-4733.2008.00355.x.

17. BobrikA, DanishevskiK, EroshinaK, McKeeM (2005) Prison health in Russia: the larger picture. J Public Health Policy 26: 30–59 doi:10.1057/palgrave.jphp.3200002.

18. World Health Organization (2011) Global Health Observatory Data Repository: mortality and burden of disease—life expectancy: life tables [database]. Available: http://apps.who.int/gho/data/. Accessed 21 June 2011.

19. World Health Organization (2011) Global Health Observatory Data Repository: health systems—health financing [database]. Available: http://apps.who.int/gho/data/. Accessed 21 June 2011.

20. WinqvistN, BjörkJ, MiörnerH, BjörkmanP (2011) Long-term course of Mycobacterium tuberculosis infection in Swedish birth cohorts during the twentieth century. Int J Tuberc Lung Dis 15: 736–740 doi:10.5588/ijtld.10.0683.

21. AertsA, HabouzitM, MschiladzeL, MalakmadzeN, SadradzeN, et al. (2000) Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis 4: 1104–1110.

22. BalabanovaY, DrobniewskiF, FedorinI, ZakharovaS, NikolayevskyyV, et al. (2006) The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation. Respir Res 7: 44 doi:10.1186/1465-9921-7-44.

23. BonnetM, SizaireV, KebedeY, JaninA, DoshetovD, et al. (2005) Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis 9: 1147–1154.

24. DrobniewskiF, TaylerE, IgnatenkoN, PaulJ, ConnollyM, et al. (1996) Tuberculosis in Siberia: 1. an epidemiological and microbiological assessment. Tuber Lung Dis 77: 199–206.

25. KrivonosPS, AvdeevGS (2005) [Tuberculosis control in the penitentiaries of the Republic of Belarus: state-of-the-art and prospects.]. Probl Tuberk Bolezn Legk 5: 22–25.

26. NechaevaOB, SkachkovaEI, PodymovaAS (2005) [Tuberculosis in the prisons of the Sverdlovsk Region.]. Probl Tuberk Bolezn Legk 5: 16–18.

27. Republican Center for Tuberculosis Control (2009) [Statistical information on tuberculosis for years 2007–2008 in the Republic of Tajikistan.] Dushanbe (Tajikistan): Ministry of Health, Republic of Tajikistan.

28. CokerRJ, DimitrovaB, DrobniewskiF, SamyshkinY, BalabanovaY, et al. (2003) Tuberculosis control in Samara Oblast, Russia: institutional and regulatory environment. Int J Tuberc Lung Dis 7: 920–932.

29. LeimaneV, LeimansJ (2006) Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes. Euro Surveill 11: 29–33.

30. World Health Organization (2011) CHOosing Interventions that are Cost Effective (WHO-CHOICE): cost-effectiveness thresholds. Available: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 21 June 2011.

31. PurohitS, SisodiaR, GuptaP, SarkarS, SharmaT (1983) Fiberoptic bronchoscopy in diagnosis of smear negative pulmonary tuberculosis. Lung India 1: 143–146.

32. de GraciaJ, CurullV, VidalR, RibaA, OrriolsR, et al. (1988) Diagnostic value of bronchoalveolar lavage in suspected pulmonary tuberculosis. Chest 93: 329–332.

33. WongthimS, UdompanichV, LimthongkulS, CharoenlapP, NuchprayoonC (1989) Fiberoptic bronchoscopy in diagnosis of patients with suspected active pulmonary tuberculosis. J Med Assoc Thai 72: 154–159.

34. SaglamL, AkgunM, AktasE (2005) Usefulness of induced sputum and fibreoptic bronchoscopy specimens in the diagnosis of pulmonary tuberculosis. J Int Med Res 33: 260–265.

35. DolanK, KiteB, BlackE, AceijasC, StimsonGV (2007) HIV in prison in low-income and middle-income countries. Lancet Infect Dis 7: 32–41 doi:10.1016/S1473-3099(06)70685-5.

36. World Health Organization Stop TB Department, World Health Organization Department of HIV/AIDS, World Health Organization Department of Child and Adolescent Health and Development (2004) TB/HIV: a clinical manual, 2nd edition. Geneva: World Health Organization.

37. DattaM, RadhamaniMP, SadacharamK, SelvarajR, RaoDL, et al. (2001) Survey for tuberculosis in a tribal population in North Arcot District. Int J Tuberc Lung Dis 5: 240–249.

38. GopiPG, SubramaniR, RadhakrishnaS, KolappanC, SadacharamK, et al. (2003) A baseline survey of the prevalence of tuberculosis in a community in south India at the commencement of a DOTS programme. Int J Tuberc Lung Dis 7: 1154–1162.

39. LewisJJ, CharalambousS, DayJH, FieldingKL, GrantAD, et al. (2009) HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 180: 1271–1278 doi:10.1164/rccm.200806-846OC.

40. ChurchyardGJ, FieldingKL, LewisJJ, ChihotaVN, HanifaY, et al. (2010) Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. AIDS 24 (Suppl 5) S19–S27 doi:10.1097/01.aids.0000391018.72542.46.

41. den BoonS, WhiteNW, van LillSWP, BorgdorffMW, VerverS, et al. (2006) An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys. Int J Tuberc Lung Dis 10: 876–882.

42. BoehmeCC, NabetaP, HillemannD, NicolMP, ShenaiS, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005–1015 doi:10.1056/NEJMoa0907847.

43. MatthysF, RigoutsL, SizaireV, VezhninaN, LecoqM, et al. (2009) Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS ONE 4: e7954 doi:10.1371/journal.pone.0007954.

44. BonnetM, PardiniM, MeacciF, OrrùG, YesilkayaH, et al. (2011) Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE 6: e23081 doi:10.1371/journal.pone.0023081.

45. Lalor MK, Allamuratova S, Tiegay Z, Khamraev AK, Greig J, et al.. (2011) Treatment outcomes in multi drug resistant TB patients in Uzbekistan [abstract]. 42nd Union World Conference on Lung Health; 26–30 October 2011; Lille, France.